Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

Chimeric Therapeutics initiates second dose cohort in chlorotoxin CAR T cell phase 1 trial

% of readers think this story is Fact. Add your two cents.

Chimeric Therapeutics Ltd (ASX:CHM) has initiated the treatment of the first patient in the second dose cohort in City of Hope’s Phase 1 clinical trial evaluating the safety and tolerability of its chlorotoxin CAR T (CLTX CAR T) cell therapy. 

The treatment of the first patient in the second dose cohort marks the introduction of dual routes of administration of CLTX CAR T cells with both intracranial intratumoral (ICT) and intracranial intraventricular (ICV) dosing. 

“Significant milestone”

Chimeric Therapeutics chief operating officer Jennifer Chow said: “We are very encouraged by the continued progress of the trial, moving to this important next phase with dose escalation and dual routes of administration.

“This is another significant milestone in the development of this important therapy for patients with progressive or recurrent glioblastoma.”

Progressive or recurrent glioblastoma

The second dose cohort will receive a total target dose of 88 × 106 CLTX CAR T cells.

City of Hope’s Phase 1 clinical trial is expected to enrol 18 to 36 patients with MMP2+ progressive or recurrent glioblastoma over a 24- month period.

CLTX CAR T therapy

CLTX CAR T cell therapy is a potentially best-in-class CAR T cell therapy that has the potential to address the high unmet medical need of patients with recurrent/progressive glioblastoma (GBM).

Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope.

CLTX CAR T cell therapy uniquely utilises CLTX, a peptide derived from scorpion toxin, as the tumour-targeting component of the chimeric antigen receptor (CAR).

CLTX has been shown in preclinical models to bind more broadly and specifically to GBM cells than other targets like EGFR, HER2 or IL13Rα2. In preclinical models,

CLTX CAR T cells also demonstrated potent antitumor activity against GBM while not exhibiting any off-tumour recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Report abuse


    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    Load more ...




    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.